A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination with Carboplatin/Gemcitabine/Pembrolizumab in Patients with Chemotherapy-Nave Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Study of Berzosertib Compared to Chemotherapy for Patients with Non-Small Cell Lung Cancer
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT9883
U.S. Govt. ID: NCT04216316
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the usual treatment (carboplatin, gemcitabine, and pembrolizumab) alone to using berzosertib (M6620, VX-970) plus the usual treatment for patients with squamous non-small cell lung cancer. The addition of berzosertib (M6620, VX-970) to the usual treatment could prevent your cancer from getting worse. But, it could also cause side effects, which the study doctors want to monitor. Another purpose of the study is to check the level of the study drugs in your blood (pharmacokinetics). Another objective of the study is to see if people with a certain genetic mutation respond better or worse to the study drugs. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug increases the time that the patient lives without his or her disease getting worse compared to the usual approach.
This study is closed
Investigator
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Non-Small Cell Lung Cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162